Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that repurposing irinotecan inhibits FAR1-driven macrophage ferroptosis and gut barrier breakdown in sepsis, highlighting a novel host-directed therapeutic strategy.
Intestinal barrier breakdown is a key driver of sepsis-related multiple organ dysfunction; however, the metabolic mechanisms underlying this process remain poorly understood. In this study, by integrating multiomic analysis with machine learning on clinical and experimental data, we identified fatty acyl-CoA reductase 1 (FAR1) as a critical regulator that promotes ferroptotic susceptibility in sepsis. FAR1 was markedly upregulated in septic macrophages, promoting polyunsaturated ether phospholipid remodeling and lipid peroxidation involving the ACSL4/GPX4 metabolic-regulatory network. We repurposed irinotecan as a FAR1-targeting compound through pharmacological sensitivity screening and subsequent validation. Beyond its canonical function as a topoisomerase I inhibitor, irinotecan exhibited a noncanonical activity by directly interacting with FAR1 in a Gly252-dependent manner. This interaction suppresses FAR1-associated ether lipid metabolic remodeling, thereby attenuating ferroptotic responses and preserving the "gatekeeper" function of intestinal macrophages. In preclinical sepsis models, low-dose irinotecan attenuated macrophage ferroptotic responses, restored mitochondrial integrity, alleviated intestinal barrier dysfunction, and improved survival. Our findings provide evidence supporting a "target-drug-mechanism" framework and highlight the potential repurposing of irinotecan as a host-directed therapeutic strategy for sepsis, particularly in contexts associated with elevated FAR1 expression.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: